| 000 | 01310 a2200325 4500 | ||
|---|---|---|---|
| 005 | 20250514161148.0 | ||
| 264 | 0 | _c20031209 | |
| 008 | 200312s 0 0 eng d | ||
| 022 | _a1537-6591 | ||
| 024 | 7 |
_a10.1086/376911 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSulkowski, Mark S | |
| 245 | 0 | 0 |
_aAnemia in the treatment of hepatitis C virus infection. _h[electronic resource] |
| 260 |
_bClinical infectious diseases : an official publication of the Infectious Diseases Society of America _c2003 |
||
| 300 |
_aS315-22 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAnemia _xchemically induced |
| 650 | 0 | 4 |
_aAntiviral Agents _xadverse effects |
| 650 | 0 | 4 | _aEpoetin Alfa |
| 650 | 0 | 4 |
_aErythropoietin _xtherapeutic use |
| 650 | 0 | 4 |
_aHIV Infections _xcomplications |
| 650 | 0 | 4 | _aHepacivirus |
| 650 | 0 | 4 |
_aHepatitis C, Chronic _xcomplications |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInterferon-alpha _xadverse effects |
| 650 | 0 | 4 | _aRecombinant Proteins |
| 650 | 0 | 4 |
_aRibavirin _xadverse effects |
| 773 | 0 |
_tClinical infectious diseases : an official publication of the Infectious Diseases Society of America _gvol. 37 Suppl 4 _gp. S315-22 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1086/376911 _zAvailable from publisher's website |
| 999 |
_c14323521 _d14323521 |
||